Xuebijing combined with ulinastation benefits patients with sepsis: A meta-analysis

American Journal of Emergency Medicine

Volumn 36, Issue 3, 2018, Pages 480-487

  Zheng, Jianfei ^a,b   Xiang, Xudong ^a,b   Xiao, Bing ^a   Li, Huixia ^c   Gong, Xun ^a   Yao, Shuo ^a   Yuan, Ting ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN PROVINCIAL MATERNAL AND CHILD HEALTH CARE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROCALCITONIN; ULINASTATIN; UNCLASSIFIED DRUG; XUEBIJING; GLYCOPROTEIN; HERBACEOUS AGENT; TRYPSIN INHIBITOR;

ARTIFICIAL VENTILATION; CLINICAL EFFECTIVENESS; DRUG EFFECT; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; COMBINATION DRUG THERAPY;

DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; GLYCOPROTEINS; HUMANS; SEPSIS; TRYPSIN INHIBITORS;

EID: 85041107320     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2017.12.007     Document Type: Review

References (35)

1. Lam, S.M., Lau, A.C., Lam, R.P., Yan, W.W., Clinical management of sepsis. Hong Kong Med J 23:3 (2017), 296–305.
2. Kuhn, S.O., Meissner, K., Rehberg, S., Fluid resuscitation in sepsis: “get the balance right”. Crit Care Med 45:3 (2017), 555–556.
3. Carrillo-Esper, R., Carrillo-Cordova, J.R., Carrillo-Cordova, L.D., Epidemiological study of sepsis in Mexican intensive care units. Cir Cir 77:4 (2009), 301–308 [279-285].
4. Plotkin, L.L., Use of vasopressin to correct hemodynamic disorders in patients with abdominal sepsis. Anesteziol Reanimatol 2 (2007), 47–49.
5. Matter, M.L., Shvetsov, Y.B., Dugay, C., Haiman, C.A., Le Marchand, L., Wilkens, L.R., et al. High mortality due to sepsis in Native Hawaiians and African Americans: the multiethnic cohort. PLoS One, 12(5), 2017, e178374.
6. Gao, J., Kong, L., Liu, S., Feng, Z., Shen, H., Liu, Q., A prospective multicenter clinical study of Xuebijing injection in the treatment of sepsis and multiple organ dysfunction syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 27:6 (2015), 465–470.
7. Y, C., S, L.C., The effectiveness of XueBiJing injection in therapy of sepsis: a multicenter clinical study. Chin J Emer Med 22:2 (2013), 130–135.
8. Li, J., Li, N.P., Gu, Y.F., Yang, X., Lu, X.B., Cong, J.N., et al. Dynamic activity of NF-kappaB in multiple trauma patients and protective effects of ulinastain. Chin J Traumatol 14:6 (2011), 354–358.
9. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7), 2009, e1000097.
10. Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
11. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
12. Song, F., Gilbody, S., Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ, 316(7129), 1998, 471.
13. Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50:4 (1994), 1088–1101.
14. Mao, X.S., Lv, T., Meng, D.L., Zhou, L., Ying, L.J., Jin, L.Z., Clinical and mechnism study of Xuebijing injection and ulinastatin in the treatment of patients with severe sepsis. Chin J Crit Care Med 12 (2008), 1077–1080.
15. Ye, D.W., Wu, J.G., Clinical study of Xuebijing injection and ulinastatin in the treatment of patients with sepsis. Chin J Primary Med & Pharm 17:4 (2010), 514–515.
16. Zhang, C., Luo, H., Zhang, S., Zhang, W.X., Effects of Xuebijing and ulinastatin on coagulation function in patients with sepsis. J Inter Intensive Med 16:3 (2010), 145–147.
17. Yang, M., Effects of Ulinastatin Combined With Xuebijing on Immune Function in Patients With Sepsis. 2011, Zhengjiang, 2010209–2010211.
18. An, N., He, J.Y., Wang, Y.X., Honh, Q.Q., Study of ulinastatin combined with Xuebijing in treatment of severe sepsis. Prog Mod Biomed 11:15 (2011), 2898–2900.
19. Wu, X.M., Dai, J.W., Wu, J.M., Clinical study of Xuebijing injection and ulinastatin in the treatment of patients with sepsis. J Clin Res 10 (2012), 1980–1981.
20. Zhou, Y.P., Chen, X.W., Zhang, C.X., Wan, L., Shen, Q.X., Wang, B., Effects of using both Ulinastain and Xuebijing on the sepsis of burn. Chin J Injury Repair Wound Healing 7:1 (2012), 72–75.
21. Jiang, L., Mao, X.S., Clinical efficacy assessment of Chinese traditional medicine preparation in the treatment of severe sepsis. Chin J Hosp 33:13 (2013), 1078–1080.
22. Zhao, G.K., Liu, Y.H., Clinical efficacy assessment of Xuebijing and ulinastatin preparation in the treatment of severe sepsis. Lab Med Clin 20 (2013), 2718–2720.
23. Zhou, C.W., Fang, Z.C., Clinical study of Xuebijing injection and ulinastatin in the treatment of patients with sepsis. Clin Pulm Med 18:4 (2013), 647–648.
24. Zeng, F.J., Chen, F.L., Chen, S.M., Peng, N., Xu, X.W., Protective effects of Xuebijing and ulinastatin on myocardial injury in patients with sepsis. Guangdong Med J 34:4 (2013), 616–618.
25. Wang, Z.B., Clinical study of Xuebijing injection and ulinastatin in treatment of 36 patients with sepsis. J Hainan Med University 20:3 (2014), 362–365.
26. Wang, H., Liu, K.J., Hu, M., Protective effect of ulinastatin combined with Xuebijing on multiple organ function in patients with sepsis. Chin J Integr Med S1 (2014), 113–116.
27. Chen, Y.J., Gao, Y.Q., Peng, Y.W., The clinical study of ulinastatin and Xuebijing on elderly patients with severe pneumonia. J Emerg Med 19:4 (2014), 269–270 [273].
28. Yi, C.F., Fang, Y.H., Effects of ulinastatin combined with Xuebijing on Pyemia. Pract Clin Med 15:1 (2014), 19–20 [26].
29. Zhang, J., Qiu, Y., Clinical study of ulinastatin combined with Xuebijing on sepsis with septic shock. Chin Foreign Med Res 21 (2015), 37–38 [39].
30. Cheng, B., Xie, G., Yao, S., Wu, X., Guo, Q., Gu, M., et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35:11 (2007), 2538–2546.
31. Kleinpell, R., Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated). Crit Care Nurse 23:3 (2003), 16–29 [67-68].
32. Han, D., Shang, W., Wang, G., Sun, L., Zhang, Y., Wen, H., et al. Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: a meta-analysis. Int Immunopharmacol 29:2 (2015), 377–382.
33. Atal, S.S., Atal, S., Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome. J Basic Clin Physiol Pharmacol 27:2 (2016), 91–99.
34. Liu, G., Li, Q., Meta-analysis of Xuebijing joint ulinastatin treating sepsis. Value Health, 17(7), 2014, A807.
35. Khakpour, S., Wilhelmsen, K., Hellman, J., Vascular endothelial cell Toll-like receptor pathways in sepsis. Innate Immun 21:8 (2015), 827–846.